Fenofibrates Get a Second Look

Research shows popular drugs fail to lower cardiovascular risk for most patients already taking a statin.

The findings of the large Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, published online in New England Journal of Medicine on March 14, 2010, are giving physicians cause to rethink how some lipid abnormalities are treated. The trial found that combination therapy with fenofibric acid and statins was no better than statins alone at reducing cardiovascular risk in patients with diabetes.
To continue reading this article or issue you must be a paid subscriber. Sign in

Subscribe to Heart Advisor

Get the next year of Heart Advisor for just $20. And access all of our online content - over 2,000 articles - free of charge.
Subscribe today and save 38%. It's like getting 5 months FREE!
Already Subscribed?
Click Here to Sign In | Forgot your password? | Activate Web Access